Beyond monoamines: glutamatergic function in mood disorders.
about
Sigma receptors: potential targets for a new class of antidepressant drugGlutamate and neurotrophic factors in neuronal plasticity and diseaseEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewZinc in the Glutamatergic Theory of DepressionA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesStructural and synaptic plasticity in stress-related disordersCurrent investigational drugs for major depressionDynamic changes in extracellular release of GABA and glutamate in the lateral septum during social play behavior in juvenile rats: Implications for sex-specific regulation of social play behavior.Inflammatory biomarkers and depressionEnhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1)Revisiting the monoamine hypothesis of depression: a new perspectiveDietary and botanical anxiolytics.Which clinical and experimental data link temporal lobe epilepsy with depression?Don't be afraid to treat depression in patients with epilepsy!Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder.Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder.Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insulaMagnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disordersGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Therapeutic options for treatment-resistant depression.Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzoleNovel drugs and therapeutic targets for severe mood disorders.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy studyAMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role.Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedoniaD-serine as a gliotransmitter and its roles in brain development and disease.Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male miceThe immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder.Gliogenesis and glial pathology in depression.Neurotransmission and bipolar disorder: a systematic family-based association study.Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.Mapping of QTLs for oral alcohol self-administration in B6.C and B6.I quasi-congenic RQI strainsEarly intervention in bipolar disorder, part I: clinical and imaging findings.Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression.Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depressionTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
P2860
Q24567770-1E1407F9-6C16-4CC7-B92F-34D3F8C00037Q24653626-D2D64B9C-3302-455D-9FE0-3CA493D80FBFQ26743786-BF03AE2D-DE6D-4779-9486-66C47DC76850Q26786214-DCF3003F-ABCF-4C61-B934-B5B715B538EEQ26786354-0E446794-2456-4545-931D-32B4B0F629D0Q26866209-18AA4196-7873-42E9-9DFD-899DBFB8B156Q28244223-B5307A1E-98E2-400D-BC89-399965BD95D0Q28266736-58F4F52E-DFE3-4255-B483-E65331B6FDDCQ28288750-68FF22DB-5989-46F7-A21C-3FD68871E066Q28593091-2DF9CFAA-630C-4CFD-87E8-18753E190CFBQ28660308-EDF0B000-881B-4B6C-8F1F-77CD331AF132Q30455278-CA50E01D-D642-4B7E-A178-8169AC2A895DQ31130656-B58C5101-FC56-4B56-83ED-AC5B7E1E4787Q33365195-505F5C34-BCCD-4A8B-828C-E557E6459D61Q33678466-2D5900F3-65D7-4FEB-8586-65E716E9B910Q33838237-B6354D40-74FE-46C4-B166-DD41F78C983FQ34038694-5BCC558B-A9A0-4C1B-AE89-2311E13C3C8BQ34204211-3FF86BFC-5A6B-414D-9805-1094505B8F36Q34330678-93BB62C9-6DFE-4B72-929A-E79220B90A80Q34615947-0B5294A2-FC3F-48C8-8DFF-35A2A3F0030CQ34661581-755D630A-7B9B-4FFA-AF49-82DFD7DB6F55Q34732759-133D9861-9D87-49D3-A90A-D46FF5E55A3FQ34766451-F0789EC1-8868-4389-832D-CA29AB094059Q35019612-7D78061E-7F11-411D-8215-3EA4DFEEAA6EQ35753372-E47293B1-ED18-45D7-8D34-354DE99739E9Q35944981-739E2F6A-5C87-48E4-8F9E-3FCE859467C1Q36234249-CB080DB5-8C8F-426B-9EFE-9C3CC5862618Q36785486-92BFEE08-953C-4CB1-95E9-7F28889906ABQ36788384-2CBC845C-5239-4F89-AD86-56C112F5057BQ36800963-017F9A6B-B397-4D56-AC6F-A8DF60F49B56Q36812629-27ECAE98-7F0C-4A53-AD29-137855900B0DQ36825936-7360BF16-900D-473D-A878-1EDD69100F92Q36952439-CB16BE32-3D42-4812-9B66-89C3566BBC90Q36960864-508B76EA-6A0F-4AAC-8002-69AAC6F362A9Q36984013-45071353-7F9F-42BE-BB20-9E69667A3BC0Q36998137-6BDC37C4-781B-400F-ADE6-BD634A676F02Q37035662-CB7FC8B4-C0F2-46B3-A666-FF0EAEE7C7D8Q37104018-6EAC3550-235A-48D5-9584-D17C70159D14Q37128042-52F6875B-3EDE-4BFC-9099-169CDBE83858Q37143117-A5D9C2EF-B9EC-46E2-951B-72DCA18CC8DC
P2860
Beyond monoamines: glutamatergic function in mood disorders.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Beyond monoamines: glutamatergic function in mood disorders.
@ast
Beyond monoamines: glutamatergic function in mood disorders.
@en
type
label
Beyond monoamines: glutamatergic function in mood disorders.
@ast
Beyond monoamines: glutamatergic function in mood disorders.
@en
prefLabel
Beyond monoamines: glutamatergic function in mood disorders.
@ast
Beyond monoamines: glutamatergic function in mood disorders.
@en
P1433
P1476
Beyond monoamines: glutamatergic function in mood disorders.
@en
P2093
Akira Kugaya
Gerard Sanacora
P304
P356
10.1017/S1092852900010403
P577
2005-10-01T00:00:00Z